Technical Analysis for IVVD - Invivyd, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Lower Bollinger Band Walk | Weakness | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Bullish Engulfing | Bullish | 0.09% | |
Stochastic Buy Signal | Bullish | 0.09% | |
Lower Bollinger Band Walk | Weakness | 0.09% | |
New 52 Week Low | Weakness | 0.09% | |
Outside Day | Range Expansion | 0.09% | |
Wide Bands | Range Expansion | 0.09% | |
Lower Bollinger Band Touch | Weakness | 0.09% |
Alert | Time |
---|---|
2x Volume Pace | about 20 hours ago |
60 Minute Opening Range Breakdown | about 21 hours ago |
1.5x Volume Pace | about 21 hours ago |
Down 3% | about 21 hours ago |
Down 2 % | about 21 hours ago |
Get a Trading Assistant
- Earnings date: 11/07/2024
Invivyd, Inc. Description
Invivyd, formerly Adagio Therapeutics (Nasdaq: ADGI), is a biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. Invivyd’s technology works at the intersection of evolutionary virology, predictive modeling, and antibody engineering, and is designed to identify high-quality, long-lasting antibodies with a high barrier to viral escape. The company is generating a robust pipeline of products for use in both prevention and treatment of disease. NVD200, Invivyd’s first antibody combination product for COVID-19, is expected to enter the clinic in Q1 2023. Invivyd’s most advanced pipeline candidate is adintrevimab, an investigational monoclonal antibody which has demonstrated clinically meaningful results in global Phase 3 clinical trials against multiple variants of concern for the prevention and treatment of COVID-19. Adintrevimab is not approved for use in any country. The safety and efficacy of adintrevimab have not been established. The company also has multiple discovery stage candidates for the prevention of seasonal influenza.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Biology Disease Immunology Antibodies Monoclonal Antibodies Antibody Viral Disease Seasonal Influenza Symphogen
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 5.195 |
52 Week Low | 0.72 |
Average Volume | 477,421 |
200-Day Moving Average | 1.93 |
50-Day Moving Average | 0.98 |
20-Day Moving Average | 0.91 |
10-Day Moving Average | 0.87 |
Average True Range | 0.08 |
RSI (14) | 37.50 |
ADX | 18.54 |
+DI | 16.62 |
-DI | 27.51 |
Chandelier Exit (Long, 3 ATRs) | 0.84 |
Chandelier Exit (Short, 3 ATRs) | 0.95 |
Upper Bollinger Bands | 1.09 |
Lower Bollinger Band | 0.72 |
Percent B (%b) | 0.13 |
BandWidth | 41.41 |
MACD Line | -0.06 |
MACD Signal Line | -0.03 |
MACD Histogram | -0.0209 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 0.86 | ||||
Resistance 3 (R3) | 0.87 | 0.83 | 0.85 | ||
Resistance 2 (R2) | 0.83 | 0.81 | 0.83 | 0.84 | |
Resistance 1 (R1) | 0.80 | 0.80 | 0.82 | 0.80 | 0.84 |
Pivot Point | 0.77 | 0.77 | 0.78 | 0.77 | 0.77 |
Support 1 (S1) | 0.74 | 0.75 | 0.75 | 0.74 | 0.70 |
Support 2 (S2) | 0.71 | 0.73 | 0.71 | 0.69 | |
Support 3 (S3) | 0.67 | 0.71 | 0.69 | ||
Support 4 (S4) | 0.67 |